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ABSTRACT: Introduction: Neural development is an 
enormously complex and dynamic process. From very early in 
brain development ‘immune cells’ play a key role in a number 
of processes including the formation and refinement of neural 
circuits, as well as sexual differentiation. There is a growing 
body of evidence that the immune system also plays an important 
role in the pathobiology of several neurodevelopmental and 
neuropsychiatric disorders. Objective: The goal of this article is 
to review the currently available data concerning the role of the 
‘immune system’ in normal brain development, as well as its role 
in the pathobiology of neurodevelopmental and neuropsychiatric 
disorders. Methodology: We conducted a traditional literature 
search using PubMed and recent special issues of journals to 
locate relevant review articles. Results: The cellular and molecular 
processes that make up our ‘immune system’ are crucial to normal 
brain development and the formation and maintenance of neural 
circuits. It is also increasingly evident that the immune system 
and neuroinflammation play important roles in the pathobiology 
of at least a subset of individuals with Autism Spectrum Disorder 
(ASD), schizophrenia, obsessive-compulsive disorder, Tourette 
syndrome and mood disorders, such as depression, as well 
as autoimmune and neurodegenerative disorders. Emerging 
evidence also points to the importance of the ‘gut-brain 
axis’ and an individual’s microbiome, which can impact an 
individual’s somatic and mental well-being. Conclusions: There 
are multidirectional interconnections across multiple biological 
systems in our brains and bodies that are mediated in part by the 
immune system. At present, however, the ‘promise’ of this field 
remains greater than the ‘deliverables’. Time will tell whether 
novel interventions will be developed that will make a positive 
difference in the care of our patients. It is also possible that valid 
biomarkers will emerge that will guide a more personalized 
approach to treatment. 
Keywords: Immune system; Immunology; Neurodevelopmental 
disorders; Microglia; Immunity, maternally-acquired; 
Neuroimmunomodulation; Cytokines; Autistic disorder; Autism 
spectrum disorder; Schizophrenia; Obsessive-compulsive 
disorder; Tourette syndrome; Depression; Mood disorders; Stress, 
psychological.
RESUMO: Introdução: O desenvolvimento neural é um 
processo extremamente complexo e dinâmico. Tao pronto se 
inicia o desenvolvimento do cérebro, as “células imunológicas” 
desempenham um papel fundamental em vários processos, 
incluindo a formação e aperfeiçoamento de circuitos neurais, 
bem como a diferenciação sexual. Há um crescente corpo de 
evidências de que o sistema imunológico também desempenha 
um papel importante na fisiopatologia de diversos transtornos 
neurodesenvolvimentais e neuropsiquiátricos. Objetivo: O objetivo 
deste artigo é revisar os dados atualmente disponíveis sobre o 
papel do “sistema imunológico” em relação ao desenvolvimento 
normal do cérebro, bem como a fisiopatogenia dos transtornos 
de neurodesenvolvimento e neuropsiquiátricos. Metodologia: Foi 
realizada uma pesquisa bibliográfica tradicional para localizar 
artigos de revisão relevantes. Resultados: Os processos celulares 
e moleculares que compõem o nosso “sistema imunológico” são 
cruciais para o desenvolvimento normal do cérebro e a formação 
e manutenção de circuitos neurais. É cada vez mais evidente que 
o sistema imunológico e neuroinflamação desempenham papéis 
importantes na etiopatogenia de pelo menos um subconjunto de 
indivíduos com autismo, esquizofrenia, transtorno obsessivo-
compulsivo, síndrome de Tourette, depressão e transtornos do 
humor, bem como distúrbios autoimunes e neurodegenerativos. 
Evidências emergentes também apontam para a importância do 
eixo intestino-cerebral e do microbioma de um indivíduo em 
relação à sua saúde e bem-estar somático e mental. Conclusões: 
Existem interconexões multidirecionais entre múltiplos sistemas 
biológicos em nossos cérebros e corpos que são mediados em parte 
pelo sistema imunológico. No momento, no entanto, a “promessa” 
desse campo continua sendo maior do que os “resultados finais”. 
O tempo dirá se novas intervenções serão desenvolvidas que farão 
uma diferença positiva no cuidado de nossos pacientes. Também 
é possível que surjam biomarcadores válidos que orientarão uma 
abordagem mais personalizada ao tratamento.
Descritores: Sistema imunitário; Imunologia; Transtornos do 
neurodesenvolvimento; Microglia; Imunidade materno-adquirida; 
Neuroimunomodulação; Citocinas; Transtorno autístico; 
Transtorno do espectro autista; Esquizofrenia; Transtorno 
obsessivo-compulsivo; Síndrome de Tourette; Depressão; 
Transtornos do humor; Estresse psicológico.
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INTRODUCTION
In the not too distant past, the ‘immune system’ was viewed as a complex set of cellular and 
molecular processes that protect us against pathogens - 
from viruses and bacteria to parasitic worms. It is now 
clear that the cellular and molecular processes that make 
up our ‘immune system’ are also crucial to normal brain 
development and the formation of neural circuits. It is 
also becoming increasingly evident that the immune 
system plays a key role in the pathobiology of a number 
of neuropsychiatric and neurodegenerative disorders. 
This review summarizes the currently available literature 
across multiple domains and highlights how a deeper 
understanding of neuroimmunology is transforming the 
field of neuropsychiatry. A hallmark of this emerging area 
of science is the vast complexity of the nervous and immune 
systems and how interconnected they are with one another. 
METHODS
This review article summarizes information 
assembled from a number of publications and systematic 
reviews of the scientific literature and is focused on the 
interface between the immune and nervous systems from 
early embryonic development through adolescence and 
adulthood. This includes the importance of the on-going 
“cross-talk” between the two systems, as it relates to the 
emergence of neurodevelopmental and neuropsychiatric 
disorders. Examples of summarized literature include, a 
special issue of Science magazine on ‘Brain Development’ 
published in October 20181. Other examples include the 
articles published in a recent special issue of Biological 
Psychiatry on ‘Prenatal programming of neuropsychiatric 
disorders across the lifespan’ that was published earlier this 
year in January 20192. The content of earlier special issues 
of Science, Biological Psychiatry and Brain Research were 
also reviewed3-6. Additional review articles were accessed 
in PubMed by linking terms related to immunobiology 
with specific neuropsychiatric and neurodevelopmental 
disorders including Autism Spectrum Disorder (ASD), 
schizophrenia, obsessive-compulsive disorder (OCD), 
Tourette syndrome (TS), attention deficit hyperactivity 
disorder (ADHD), depression and mood disorders among 
others. In addition, PubMed searches were performed using 
key words and phrases that included: microglia, innate 
immune system, adaptive immune system, cytokines, 
maternal immune activation (MIA), neuro-immune 
network hypothesis, microbiota, microbiome, and the 
‘gut-brain axis’.
RESULTS
The emerging knowledge concerning the role that 
the immune system plays in specific neurodevelopmental 
and neuropsychiatric disorders, and several related topics 
are highlighted. They include: (i) microglia and the role 
of the immune system in early brain development; (ii) 
genetic determinants of immune function; (iii) stress, 
neuroinflammation, maternal immune activation (MIA) 
and the neuro-immune network hypothesis; and (iv) the 
microbiome and ‘gut-brain axis.’   
Microglia and the role of the immune system in normal 
brain development and neuropsychiatric disorders
Recent advances in our understanding of normal 
brain development highlight the important role played by 
the microglia7-11. Microglia are the resident macrophage 
population of the central nervous system (CNS). They 
originate from the yolk sac that colonizes the embryonic 
human CNS from as early as the 4th week of gestation and 
they constitute 5-15% of the cells in the CNS12. Microglia 
are not only among the first immune sentinels of infection, 
but they are also involved in early brain development. 
Initially, they were recognized as critical players in 
sculpting neuronal connectivity in the developing brain 
through synaptic pruning13-15. In addition to sculpting 
synaptic connectivity, emerging data show that microglia 
enter the embryonic brain before the differentiation of 
other CNS cell types and are critical regulators of early 
brain development, including regulating the number and 
maturation of neural precursors and other resident CNS 
cell types12,13. Based on preliminary studies in adult mice, 
it appears that migrating microglia develop region-specific 
and sex-specific features, including the suggestion that 
female microglia are neuroprotective while male microglia 
are pro-inflammatory in character14. Microglia have also 
been shown to relay crucial information from the periphery 
to the CNS, including signals derived from the microbiota16. 
These findings underscore the importance of studying 
neurodevelopment as part of a broader framework that 
considers nervous system interactions with microglia and 
the immune system in a ‘whole-body’ context.
Evidence from human studies suggests that microglia 
are dysfunctional in at least a subset of individuals with 
neuropsychiatric disorders, as well as in neurodegenerative 
disorders such as Alzheimer’s disease and chronic pain17. 
The range of neuropsychiatric disorders associated with 
at least some evidence of microglia dysfunction is broad 
and the list includes: Autism Spectrum Disorder (ASD), 
schizophrenia, bipolar disorder, major depression, OCD, 
and Tourette syndrome (TS)17-21. For example, postmortem 
studies of brain tissue from a small number of individuals 
with ASD have documented altered numbers of microglia in 
the dorsolateral prefrontal cortex22-24. Whole transcriptional 
analyses of postmortem brain tissue have also found that 
some individuals with ASD have altered expression of 
microglia-specific genes25,26. Similar findings in a subset 
of subjects with ASD have been documented using 
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positron emission tomography (PET). Brain regions with 
increased binding of a radiotracer to microglia included 
the cerebellum, midbrain, pons, fusiform gyri, and the 
anterior cingulate and orbitofrontal cortices27. Likewise, 
studies of postmortem brain tissue from individuals with 
schizophrenia also support the role of the immune system, 
including the activation of microglia. For example, a recent 
meta-analysis identified 41 studies reporting on 783 patients 
and 762 controls. They found convincing evidence of a 
significant increase in the density of microglia in the brains 
of schizophrenic patients compared with controls. This 
increase was most consistently observed in the temporal 
cortex28. Elevated levels of microglia immunoreactivity 
have also been reported in the cortex of depressed 
individuals, as well as in brain tissue from individuals 
who committed suicide29,30. More recently, Setiawan et al.31 
reported evidence for microglia activation during major 
depressive episodes using positron emission tomography. 
These changes were significant in the prefrontal cortex, 
anterior cingulate cortex and insula. Greater microglia 
activation in the insula was correlated with the level of 
depressive symptom severity31. 
In the case of TS and OCD, preliminary findings 
from studies of postmortem brain tissue and brain imaging 
studies also indicate that immune activation is present in 
some individuals with TS and childhood-onset OCD21,32. 
More specifically, in the postmortem study, transcriptome 
data from the caudate nucleus and putamen from 9 TS and 
9 matched control subjects identified 309 down-regulated 
and 822 up-regulated genes, in the patients with TS21. 
Using Weighted Gene Co-expression Network Analysis, 
17 differentially expressed pathways or groups of genes 
were identified33. The power of this strategy is that it 
permits investigators to examine how genes and their 
products function in concert, rather than individually. 
The top-scoring down-regulated module was enriched 
for interneuron transcripts. However, the top-scoring 
up-regulated module was enriched with immune-related 
genes, associated with both the innate and adaptive 
immune systems. The pathway analyses pointed to the 
likely role of the microglia20,21. A PET brain imaging 
study that used a radioligand associated with activation of 
the innate immune system, found evidence of microglia 
mediated neuroinflammation in the bilateral caudate 
nuclei in 12 children with TS. In this same PET study, 
neuroinflammation was also seen in the bilateral lentiform 
nucleus, as well as in the bilateral caudate nuclei, in 15 
children diagnosed with PANDAS (Pediatric Autoimmune 
Neuropsychiatric Disorders Associated with Streptococcal 
Infections). Future studies are needed to confirm these 
findings32.
PANDAS was first described by Susan Swedo and 
her team at the National Institute of Mental Health in 199834. 
The diagnostic criteria for PANDAS includes an abrupt 
“overnight” onset of OCD and other neuropsychiatric 
symptoms including tics, anxiety, emotional lability, 
enuresis, and attentional problems. The onset of PANDAS 
is in childhood. In some cases, these symptoms manifest 
a relapsing-remitting, episodic symptom course in the 
aftermath of an infection with group A beta-hemolytic 
streptococcal infections (GAS), as seen with Sydenham’s 
chorea. PANDAS has been proposed to result from 
antibodies raised against GAS cross-reacting with brain 
antigens, based in part on molecular mimicry. However, 
the targets of these antibodies are not entirely clear and 
may be heterogeneous35,36. 
Currently, PANDAS remains a controversial topic37. 
Despite continued debates about the role of GAS infections 
in the etiopathogenesis of PANDAS, experts on both 
sides of the controversy agree that a subgroup of children 
with OCD have an unusually abrupt onset of symptoms, 
accompanied by a variety of comparably severe and acute 
neuropsychiatric symptoms. The acuity of symptom onset is 
the hallmark feature of their clinical presentation and is the 
basis for the name proposed for an expanded clinical entity: 
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). 
PANS does not require specific association with GAS and 
can be related to other infectious factors38. Modifying the 
PANDAS criteria to eliminate etiologic factors and to 
clarify the time-course of the initial clinical presentation 
is a step in the right direction, in our opinion.
However, in one recent study, serum was collected 
from children with well-characterized PANDAS (n = 5) 
who responded well to a course of intravenous gamma 
globulin (IVIG) and matched controls. The serum was 
then infused into the striatum of mice39. Antibodies from 
children with PANDAS bound to ∼80% of cholinergic 
interneurons, significantly higher than the <50% binding 
seen with matched healthy controls. Remarkably, after 
treatment with IVIG, symptom improvement resolved 
in parallel with a reversal of the elevated binding of 
antibodies to cholinergic interneurons40. Individuals with 
TS have fewer cholinergic interneurons in their striatum, 
based on the examination of postmortem brain tissue41. 
Future clarification of the functional consequences of this 
specific binding may provide new opportunities to identify 




The etiology of neurodevelopmental and 
neuropsychiatric disorders is complex and involves an 
individual’s genetic background as well as exposure to 
a range of risk factors from conception onwards. For 
example, the high rates of heritability for ASD clearly 
indicate that genes play an important role in its etiology42. 
Over the past decade, a multitude of risk genes have been 
identified43. Their risk effects are highly variable, but 
many different variants converge on common biological 
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pathways, including the immune system44. Intriguingly, 
some of these risk genes are located on Chromosome 6, 
which is densely packed with genes that code for immune 
molecules, particularly molecules within the major 
histocompatibility complex (HLA)45. These HLA genes 
code for cell-surface proteins that are responsible for the 
regulation of the immune system. 
Studies of human brain tissue from individuals on 
the autism spectrum also implicate the involvement of the 
immune system. For example, transcriptomes from three 
cortical brain regions, BA10, BA14, and BA 44, from 104 
subjects with ASD were sequenced. The pathway analyses 
from this large-scale RNA sequencing effort utilized region-
matched ASD and control brains, and strongly indicated 
that microglial genes are significantly dysregulated in these 
cortical regions. This analysis also highlights the interplay 
between innate immunity and neuronal activity in the 
etiology of ASD25. Similarly, a genome-wide methylation 
study of the prefrontal cortex found a significant enrichment 
for genomic regions responsible for immune function, 
specifically hypo-methylated CpGs46,47. More recently, a 
weighted gene correlation network analysis detected 3 co-
methylation modules, which were significantly correlated 
with the ASD phenotype. These modules were enriched 
for genomic regions underlying neuronal, GABAergic, and 
immune system genes48.
The etiology of schizophrenia is also complex. Like 
ASD, there is a substantial body of data indicating that genetic 
factors, immune dysregulation and neuroinflammation are 
all involved in at least a subset of cases. Whole genome 
analyses have identified 108 conservatively defined loci that 
meet genome-wide significance49,50. Many of these genes 
are highly expressed in the brain, as well as in immune 
function, including the HLA region on chromosome 651. A 
more recent study completed a genome-wide expression 
analysis in peripheral blood mononuclear cells from U.S. 
veterans with schizophrenia (n = 52) and controls. A total 
of 167 differentially expressed genes were identified. Many 
of these genes were enriched primarily for pathways related 
to inflammatory mechanisms and immune cell trafficking52. 
TS, OCD, and ADHD are also highly heritable 
conditions53-58. Despite evidence for a substantial genetic 
contribution to disease risk, the identification and replication 
of genetic variants associated with these related conditions 
has been challenging. In the case of TS, the use of rare 
variant approaches has identified two genes of major effect. 
One is involved in synaptic development59 and another 
is associated with histaminergic transmission60. Overall, 
GWAS studies for TS, OCD and ADHD have identified a 
large number of risk genes of minor effect, some of which 
impact immune function61. For example, a GWAS study 
(1,285 TS subjects and 4,964 controls) implicated several 
pathways related to specific astrocytic, oligodendrocytic 
and microglial activity, as well as to synaptic function62. 
More recently, Tylee et al.50 re-examined the available 
GWAS data from individuals with TS, OCD, and ADHD 
and found significant genetic correlations between 
psychiatric and immune-related phenotypes based on 
genome-wide association data. These findings are also 
consistent with the findings of two large scale, population-
based, epidemiological studies from Denmark and Sweden, 
which have documented that some individuals with OCD, 
TS, and ADHD have an increased risk for developing 
an autoimmune disorder63-65. Conversely, Hounie et al.66 
some years earlier documented in a case-control study 
conducted in Brazil that a familial relationship exists 
between rheumatic fever (RF) and OCD-related disorders 
when considered in aggregate (OCD, subclinical OCD, 
TS, chronic tic disorders, transient tic disorders). If an 
individual has a family history of RF, then he/she is at 
greater risk of developing OCD and/or related disorders. 
The rate of these OCD-related conditions (ORC) among 
the first-degree relatives of rheumatic fever probands was 
significantly higher than the rate among the first-degree 
relatives of control subjects. The rate of these ORCs was 
highest among the first-degree relatives of rheumatic 
fever probands who also had an ORC. However, the rate 
of ORCs was also higher among the first-degree relatives 
of RF probands without an ORC, although the difference 
was not statistically significant66. 
Stress, Neuroinflammation, Maternal Immune 
Activation, and the Neuro-immune Network Hypothesis 
‘Stress’ includes multiple modalities that can 
be biological, social and/or psychological in character. 
Threatening physical or psychological stressors are sensed 
at many levels in the human body and the CNS. This 
information is then passed on to the hypothalamus after 
being processed by various limbic regions before it is 
communicated to the adrenal gland. This signaling pathway 
is evolutionarily conserved in mammalian species, and it is 
commonly referred to as the hypothalamic-pituitary-adrenal 
(HPA) axis. Activation of the HPA axis in response to 
stressful stimuli can, in turn, induce a variety of hormonal, 
immunological, cardiovascular and autonomic responses 
that impact multiple organ systems over the course of 
development15. Early-life adversity, sometimes referred 
to as ‘toxic stress,’ can amplify the crosstalk between the 
immune system and the neural circuits that encompass 
threat-related, reward-related, and executive control-related 
processes67. This crosstalk in the neuro-immune network 
can then, in turn, contribute to a number of somatic, 
neurodevelopmental and neuropsychiatric disorders4,68,69. 
Remarkably, in the case of mothers, stressful events 
occurring during a child’s gestation can set the stage for 
adverse outcomes much later in the child’s life4,15,67,68,70,71. 
In the case of fathers, it also appears that stressful events 
occurring pre-conception can have an adverse long-term 
impact72. 
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Epidemiological studies provide compelling 
evidence that perturbations in the prenatal and perinatal 
environments are associated with an increased risk of 
offspring developing neuropsychiatric disorders including 
ASD71,73-80, schizophrenia68,71,81-85, mood and affective 
disorders71,86-92, OCD93-95, ADHD96-98, and TS99-102. These 
studies have identified a number of factors that can 
contribute to an individual’s risk of developing one or more 
of these disorders. They range from maternal infections, 
especially those associated with high fevers and a need for 
hospitalization82, inadequate nutrition86,87 as well as stressful 
life events occurring prenatally or during the first months 
of a child’s life88.
In ASD, the link between pre-term birth and the 
emergence of ASD traits is well established103. There is 
also evidence supporting a link between immune system 
dysfunction and both pre-maturity and ASD104. Dozens 
of other environmental risk factors have been identified 
that impact the developing brain. The strongest evidence 
to date concerns Maternal Immune Activation (MIA). As 
noted above, multiple epidemiological studies implicate 
maternal infection and heightened levels of maternal 
stress during gestation and the perinatal period as risk 
factors for ASD68,70,105-110. In a recent meta-analysis of 
15 studies involving more than 40,000 cases of ASD, 
maternal infection during pregnancy was associated with an 
increased risk of ASD in the offspring. This was especially 
true for those requiring hospitalization. This risk was likely 
modulated by the individual’s genetic background, the type 
of infectious agent, the time of the exposure, and the site of 
infection79. All of this points to the importance of the neuro-
immune interface early in brain and somatic development111. 
There is also a growing body of data linking ASD with 
autoimmunity and allergies112-114. Wu et al.113 conducted 
a meta-analysis of 11 studies that found that a family 
history of any autoimmune disorder was associated with a 
28% higher risk of ASD in children. Several autoimmune 
disorders significantly contributed to this finding including 
hypothyroidism (OR=1.64), type 1 diabetes (OR=1.49), 
rheumatoid arthritis (OR=1.51), and psoriasis (OR=1.59). 
Another more recent study investigated maternal immune 
conditions during gestation, as well as the lifetime 
history of these conditions in family members. Logistic 
regression analyses included 663 children on the autism 
spectrum, 984 children with a developmental disability, 
and 915 controls. A maternal history of eczema/psoriasis 
and asthma was associated with a 20%-40% increased 
odds of both ASD and a developmental disability. In 
addition, children on the spectrum were also more likely 
to have had a history of psoriasis/eczema or allergies. No 
association was observed for paternal history of these 
immune conditions112. Interestingly, another recent study 
of a nationally representative sample of U.S. children (n = 
199,520) found a significant association of a broad range 
of allergies (food, respiratory, and skin) with ASD114. In the 
immune-mediated subtype of ASD, it is possible that this 
association may impact the composition of an individual’s 
microbiome which may affect the functioning of the ‘gut-
brain axis’115.
Finally, there have also been several studies 
examining the peripheral immune markers associated 
with ASD. For better or worse, the scientific literature is 
inconsistent in that no single marker has been found to be 
abnormal consistently across all of the studies116-121. One of 
the most compelling studies was performed at University 
of California, Davis and involved an examination of 
neonatal blood spots from 214 children with ASD (141 
severe, 73 mild/moderate), 27 children with developmental 
delays; and 62 typically developing children. Levels of 17 
cytokines and chemokines were compared across groups 
and in relation to developmental and behavioral domains. 
The levels of Interleukin (IL)-1β & IL-4 in the neonatal 
blood specimens were independently associated with 
ASD. Elevated IL-4 was associated with the severe ASD 
phenotype and IL-1β was associated with the mild/moderate 
ASD phenotype. IL-4 was also negatively associated with 
nonverbal cognitive ability122. Fewer studies have examined 
the CNS directly, through the cerebrospinal fluid (CSF) 
or brain tissues. Vargas et al.23 found increased levels 
of pro-inflammatory and immunomodulatory cytokines, 
differentially expressed across the cortical regions in post-
mortem samples from individuals with ASD (n = 11). In 
contrast, Pardo et al.121 were able to track immune markers 
in the CSF longitudinally. They found striking differences 
in the expression of selected cytokines, immune-related 
growth factors, and chemokines that varied over time, when 
comparing ASD and neurotypical samples.
The environmental risk factors associated with 
an increased risk of developing schizophrenia include: 
advanced paternal age (>50 y.o. at birth), prenatal maternal 
malnutrition, prenatal infections (influenza), obstetrical 
complications and a low birth weight85,123-126. There is 
also a growing body of data linking schizophrenia with 
autoimmunity and allergies127-129. 
Clinical and epidemiological studies have also 
explored a number of potential pre- and perinatal risk 
factors associated with the risk of developing OCD, TS and 
ADHD. These include inadequate or excessive maternal 
weight gain, maternal tobacco, alcohol and cannabis use, 
hyperemesis gravidarum, prolonged labor, preterm birth, 
and jaundice, as well as high levels of maternal depression 
and anxiety93,95-99,101,102,130. The findings vary from study to 
study and more work needs to be done before any firm 
conclusions can be reached concerning the possible role 
MIA may play in the pathogenesis of these disorders. In 
addition to these genetic and epidemiological findings, there 
is an emerging body of preliminary data that is focused 
on inflammatory markers (cytokine and immunoglobulin 
levels), immune cell populations, and gene expression 
profiling of peripheral lymphocytes. These data indicate 
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some degree of hyperactivity of both the innate and the 
adaptive immune systems in TS, childhood-onset OCD 
and ADHD131-135.  
The microbiome, perinatal nutrition and the ‘gut-brain 
axis’ 
Aberrations in the microbiome after Maternal 
Immune Activation (MIA) can lead to altered development 
of peripheral immunity, both of which can alter brain 
development. Over the past two decades, the microbiome 
has emerged as an area of great scientific interest. Human 
microbiota includes bacteria, fungi, archaea and viruses136. 
As a species, our bodies contain many more non-human 
cells than human cells137. It is now clear from both animal 
models and human studies that the composition of an 
individual’s microbiota has an impact on their health and 
wellbeing138. For example, developmentally, preclinical 
findings in animal models suggest that the gut microbiome 
plays a pivotal role in regulating microglial maturation and 
function and that this bidirectional crosstalk between the 
gut and the brain may influence disease pathogenesis139. 
Indeed, animal models have provided the most compelling 
evidence that gut bacteria and their metabolites play a 
role in CNS homeostasis and that they can directly affect 
behavior. Maternal and infant diet, stress, mode of delivery, 
e.g., vaginal vs. C-section, maternal infections, and 
antibiotic exposures all shape early microbial colonization 
patterns140,141. How enduring these patterns are, and what, 
if any, long-term phenotypic impact they have on disease 
and neurodevelopment is currently being explored. Human 
studies have been primarily correlative in nature, so caution 
is warranted and must be applied before concluding that 
the composition of an individual’s microbiota has a direct 
causal role in the pathogenesis of psychiatric disease. 
Research on the microbiome of individuals with 
ASD is the most advanced142,143 and studies are now 
underway that are exploring the impact of microbiome 
transfer therapy144. Efforts to understand the role of the 
microbiome are also underway with regard to a number 
of other disorders including schizophrenia and bipolar 
disorder145-150, TS, OCD, and related disorders including 
PANS and PANDAS151-153, major depression and mood 
disorders154,155, alcohol use and eating disorders156, as well 
as neurodegenerative disorders157. 
Another key mechanism concerns the “gut-brain 
axis.” This axis involves the neural and molecular signaling 
that takes place between the gastrointestinal (GI) tract 
and the CNS158-161. Not surprisingly, maternal stress, the 
HPA axis, the sympathetic and parasympathetic arms of 
the autonomic nervous system, as well as the individual’s 
dietary intake and the composition of their microbiome all 
play an important role. The microbiota in the GI tract can 
influence CNS functions due to its ability to synthesize a 
wide range of molecules including neurotransmitters and 
their precursors, e.g., acetylcholine, gamma-aminobutyric 
acid (GABA), serotonin, catecholamines, melatonin, and 
histamine158. These interconnected systems are established 
shortly after birth and are influenced by a number of 
factors including: maternal psychosocial stress, infections, 
antimicrobial treatments, mode of delivery and obstetrical 
complications, as well as maternal and child dietary intake 
including breast feeding130,162. Remarkably, there is now 
evidence from animal models and human studies that the 
‘microbiota-gut-brain axis’ can influence gene expression 
and brain microstructure, as well as host stress-induced 
behavior, social interactions and learning and memory task 
performance162-166. 
Another truly amazing finding is that bacteria appear 
to be present in both human (n=34) and mouse brains under 
noninfectious or nontraumatic conditions. These findings 
were presented as a poster at the Society for Neuroscience 
annual meeting in San Diego in November of 2018. 
The density of the bacteria varied by brain region, with 
abundant bacteria in the substantia nigra, hippocampus 
and prefrontal cortex. The observed bacteria were present 
in intracellular locations within astrocytes located near the 
blood brain barrier. They were also abundant adjacent to 
the blood brain barrier and within myelinated axons. RNA 
sequencing revealed that most of the bacteria were from 
three phyla common to the gut: Firmicutes, Proteobacteria, 
and Bacteroidetes167. If replicated, it will be important 
to examine postmortem tissue from individuals with 
neurodevelopmental and neuropsychiatric disorders to 
determine if gut microbiota are present and, if so, how they 
vary from disorder to disorder.
DISCUSSION
The combination of an individual’s genetic 
background, autoimmune status and a range of other factors 
including MIA and an individual’s ‘microbiota-gut-brain 
axis’ set the stage for the emergence of neurodevelopmental, 
neuropsychiatric, and neurodegenerative disorders. In some 
instances, “second hits” during childhood and adolescence, 
including stress and substance use, may be key factors 
as well. In this review we have briefly summarized the 
published data concerning the role of the immune system 
in the pathobiology of several neurodevelopmental 
and neuropsychiatric disorders including ASD and 
schizophrenia as well as OCD, ADHD and tic disorders. 
At present, the available data highlight the findings 
of epidemiological, genetic, and post-mortem studies, 
as well as, cross-sectional and longitudinal studies of 
immune activation in the periphery. We have also briefly 
summarized the results of studies that seek to characterize 
the microbiota associated with these disorders. We have 
reviewed the current state-of-the-art with regard to the 
therapeutic potential for immunomodulatory interventions 
for each of these conditions.  
247
Rev Med (São Paulo). 2019 July-Aug;98(4):241-53.
In closing, we highlight the value of animal model 
systems particularly with regard to embryonic development. 
Embryonic development captures a particularly complex 
period, in which genetic and environmental factors can 
interact to contribute to risk. In addition to clinical and 
epidemiological studies, this field of research has been 
driven by the use of animal model systems9,11,140,168-170. For 
example, animal research has documented that inflammatory 
perturbations in the developing brain can divert microglia 
from their normal physiological role to a potentially more 
pathological role, both in the short-and long-term11,171,172. 
Maternal inflammation generally can increase microglial 
density and/or activation in the offspring brain173. These 
changes begin embryonically, as demonstrated by increased 
microglial density and reactivity a few days after the mid- 
or late-gestation administration of immuno-stimulatory 
compounds such as lipopolysaccharide (LPS), which mimic 
infections by gram-negative bacteria174,175. LPS stimulates 
the production of many endogenous proinflammatory 
cytokines including interleukin-1b(IL-1b), IL-6, and tumor 
necrosis factor alpha (TNF-alpha), which, along with other 
factors, recruit, activate, and stimulate the production of 
immune cells174-176. Additionally, microglial and cytokine 
changes in the developing brain may directly influence 
synaptic plasticity as well as increase the reactivity of an 
animal’s immune system to subsequent immune challenges 
in adulthood7,177,178. 
It is also important to highlight the role of the 
placenta, as it plays a very significant role in prenatal 
immune-neurodevelopmental interactions. The placenta 
is highly immunologically specialized, and it can serve 
both as a conduit for and regulator of immune factor 
traffic at the maternal-fetal interface177. Animal models 
have also documented the transgenerational inheritance of 
behavioral and metabolic effects of paternal exposure to 
traumatic stress in early postnatal life179. In sum, differences 
certainly exist between rodents and humans that limit the 
value of animal model systems, with regard to a number 
of relevant variables including developmental timing in 
utero, placental morphology, hormone production, and 
immunoregulatory protein expression. However, the ability 
of animal model systems to posit causal mechanisms using 
experimental designs is an obvious strength170,177,180. 
Some of the unanswered questions that are 
fundamental to this area of research include how and why 
the onset of specific neuropsychiatric disorders is often 
separated by years or decades from early developmental 
disruptions associated with MIA. Despite limitations, 
animal models provide critical data supporting prenatal 
inflammatory programming of the brain and will be 
fundamentally involved as immunome-level analyses 
and other innovative methods are developed. Hopefully, 
advances in developmental neuroscience that link prenatal 
events with subsequent brain-development events will 
provide a foundation on which the pathophysiology of 
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